Skip to main content

Table 1 Study treatment arms

From: Pharmacokinetic study of two different rifabutin doses co-administered with lopinavir/ritonavir in African HIV and tuberculosis co-infected adult patients

 Day 1 to Day 14Day 15 after anti-tuberculosis initiationDay 14 after combined treatment (anti-TB and ART)
armAnti-tuberculosis aloneCombined anti-tuberculosis and ART
(for the duration of anti-TB therapy)
Pharmacokinetic monitoring
A“300 mg rifabutin + standard ethambutol-isoniazid-pyrazinamide regimen” daily for 14 days150 mg rifabutin every other day + standard ethambutol-isoniazid-pyrazinamide regimen combined with
ART regimen including 200/50 mg lopinavir/ritonavir taken twice daily
Blood taken for pharmacokinetic monitoring
B“300 mg rifabutin + standard ethambutol-isoniazid-pyrazinamide regimen” daily for 14 days300 mg rifabutin every other day + standard ethambutol-isoniazid-pyrazinamide regimen combined with
ART regimen including 200/50 mg lopinavir/ritonavir taken twice daily
Blood taken for pharmacokinetic monitoring